Copyright
©The Author(s) 2017.
World J Gastroenterol. Dec 21, 2017; 23(47): 8395-8404
Published online Dec 21, 2017. doi: 10.3748/wjg.v23.i47.8395
Published online Dec 21, 2017. doi: 10.3748/wjg.v23.i47.8395
Table 3 Comparison of the complete symptom resolution rates between dexlansoprazole and esomeprazole over one week (Subgroup analysis by gender) n (%)
| Time | Gender | Dexlansoprazole | Esomeprazole | P value |
| CSR Day 1 | Female | 13 (27.7) | 6 (15.8) | 0.192 |
| Male | 8 (23.5) | 17 (39.5) | 0.136 | |
| CSR Day 3 | Female | 18 (38.3) | 7 (18.4) | 0.046 |
| Male | 9 (26.5) | 19 (44.2) | 0.109 | |
| CSR Day 7 | Female | 26 (55.3) | 14 (36.8) | 0.090 |
| Male | 16 (47.1) | 25 (58.1) | 0.333 |
- Citation: Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK, Taiwan Acid-Related Disease Study Group. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. World J Gastroenterol 2017; 23(47): 8395-8404
- URL: https://www.wjgnet.com/1007-9327/full/v23/i47/8395.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i47.8395